Caribou Biosciences, Inc.

Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company specializing in the development of genome-edited allogeneic cell therapies for hematologic malignancies and solid tumors. The company's lead product candidates include CB-010, an allogeneic anti-CD19 CAR-T cell therapy for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma. Additionally, Caribou Biosciences is developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, and CB-020, an allogeneic CAR-NK cell therapy for solid tumors.

Products

• Allogeneic anti-CD19 CAR-T cell therapy (CB-010)

• Allogeneic anti-BCMA CAR-T cell therapy (CB-011)

• Allogeneic anti-CD371 CAR-T cell therapy (CB-012)

• Allogeneic CAR-NK cell therapy (CB-020)